Galmed Pharmaceuticals Ltd. (GLMD) Financials

GLMD Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2025 21.6 million 2.5 million
June 30, 2025 22.9 million 2.4 million
March 31, 2025 18.7 million 1.8 million
Dec. 31, 2024 18.5 million 2.2 million

GLMD Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2025 -1.9 million 105000
June 30, 2025 -1.3 million 100000
March 31, 2025 -1.2 million 101000
Dec. 31, 2024 -2.0 million 116000

GLMD Net Income

No data available :(

GLMD Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2025 19.1 million - -
June 30, 2025 20.5 million - -
March 31, 2025 15.7 million - -
Dec. 31, 2024 15.3 million - -

GLMD Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2025 5.5 million
June 30, 2025 3.9 million
March 31, 2025 1.8 million
Dec. 31, 2024 1.7 million

GLMD Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2025 - 1.1 million 1.0 million -
June 30, 2025 - 1.1 million 1.1 million -
March 31, 2025 - 634000 630000 -
Dec. 31, 2024 - 1.1 million 572000 -

GLMD Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2025 - -
June 30, 2025 - -
March 31, 2025 - -
Dec. 31, 2024 - -

GLMD

Price: $0.51

52 week price:
0.41
2.34

Earnings Per Share: -3.44 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: Israel

Volume: 176487

Ebitda: -2.7 million

Market Capitalization: 3.1 million

Links: